22
Views
19
CrossRef citations to date
0
Altmetric
Original Article

Evaluation of the Prognostic Value of Serum Soluble CD 44 in Patients with Breast Cancer

, , , , &
Pages 581-585 | Published online: 11 Jun 2009

References

  • Butcher E C. The regulation of lymphocyte traffic. Cum Top Microbiol lmmunol 1986; 128: 85–122
  • Haynes B F, Telen M J, Hole L P, et al. CD 44—a molecule involsved in leukocyte adherence and T-cell activation. Immun Today 1989; 10: 423–438
  • Arch R, Wirtb K, Hofmann M, et al. Participation in normal immune responses of a metastases-inducing splice variant of CD 44. Science 1992; 257: 682–685
  • Gunther U, Hofmann M, Rudy W, et al. A new variant of glyco-protein CD 44 confers metastatic potential to rat carcinoma cell. Cell 1991; 65: 13–24
  • Miya K L, Medina K L, Hayasi S I, et al. Monoclonal antibodies to Pgp-1/CD 44 block lymphohematopoiesis in long term bone marrow cultures. J Exp Med 1990; 171: 477–488
  • Screaton G R, Bell M V, Jackson D G, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD 44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160–12164
  • Denning S M, Le P T, Singer K H, et al. Antibodies against the CD 44 P80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol 1990; 144: 7–15
  • Webb D SA, Shimizu Y, Van Seventer G A, et al. LAF-3,CD 44 and CD 45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990; 249: 1295–1297
  • Jacobson K, Odell D, Holifield B, et al. Redistribution of a major cell surface glycoprotein during cell movement. J Cell Biol 1984; 99: 1613–1623
  • Nicolson G L. Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 1987; 47: 1473–1487
  • Hart I R, Goode N T, Wilson R E. Molecular aspects of the metastatic cascade. Biochem Biophys Acta 1989; 989: 65–84
  • Smith C W, Patton J G, Nadal Ginard B. Alternative splicing in the control of gene expression 1989; 23: 527–577
  • Mulder J-WR, Kmyt P M, Sew Nath, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD 44 proteins. Lancet 1994; 344: 1470–1472
  • Kainz C, Kohlberger P, Tempfer C, et al. Prognostic value of CD 44 splice variants in human stage III cervical cancer. Eur J Cancer 1995; 31A: 1706–1709
  • Kaufmann M, Heider K H, Sinn H P, et al. CD 44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615–619
  • Kuppner M C, Meir E V, Gauthier T H, et al. Differential expression of the CD 44 molecules in human brain tumors. Int J Cancer 1992; 50: 572–577
  • Ristamaki R, Joensuu H, Salmi M, et al. Serum CD 44 in malignant lymphoma: an association with treatment response. Blood 1994; 84: 238–243
  • Guo Y J, Liu G, Wang X, et al. Potential use of soluble CD 44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994; 54: 422–426
  • Kainz C, Tempfer C, Winkler S, et al. Serum CD 44 splice variants in cervical cancer patients. Cancer Lett 1995; 90: 231–234
  • Bloom H JG, Richardson W W. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359–377
  • The World Health Organization. Histological typing of breast tumor. Am J Clin Pathol 1982; 78: 806–816
  • Staging for carcinoma of the breast. Manual for Staging of Cancer, 3rd ed, D Beahrs, Henson, R Hutter, M Myers. J.B. Lippincott, Philadelphia 1988; 145–150
  • Sheen-Chen S M, Chen W J, Eng H L, et al. Serum-soluble in-terleukin-2 receptor concentrations in patients with breast cancer: a preliminary report. Chang Gung Med J 1998; 21: 133–138
  • Hedley D W, Friedlander M L, Taylor I W, et al. Method for analysis of cellular DNA of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333–1335
  • Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD 44 confers metastatic potential to rat carcinoma cell. Cell 1991; 65: 13–24
  • Underhill C. CD 44: the hyaluronan receptor. J Cell Sci 1992; 103: 293–298
  • Friedrichs K, Franke F, Lisboa B W, et al. CD 44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995; 55: 5424–5433
  • Tempfer C, Losch A, Heinzl H, et al. Prognostic value of immunohistochemically detected CD 44 isoforms CD 44 V5, CD 44 V6 and CD 44 V7–8 in human breast cancer. Eur J Cancer 1996; 32A: 2023–2025

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.